However, we believe that AntiPD1 monotherapy remains a central treatment in the management landscape of mutated BRAF melanoma patients and we believe that studies such as this can help frame its right place in the therapeutic decision-making algorithm. The gene discussed is BRAF; the disease is melanoma.